Lineage Cell Therapeutics (LCTX) Cash from Financing Activities (2010 - 2026)
Lineage Cell Therapeutics (LCTX) reported Cash from Financing Activities of $5.6 million for Q1 2026, up 10.25% on a YoY basis from $5.0 million in Q1 2025, and down 72.71% quarter-over-quarter from $20.4 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics has reported Cash from Financing Activities for 17 years, with the latest figure at $5.6 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 10.25% year-over-year to $5.6 million; the trailing twelve-month figure through Mar 2026 stood at $27.5 million (up 2.18% YoY), and the FY2025 full-year result was $27.0 million, down 24.84% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $5.6 million, down from $20.4 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $21.7 million in Q4 2024, with the low at -$307000.0 in Q2 2025.
- Historically, Cash from Financing Activities has averaged $4.5 million across 5 years, with a median of $807000.0 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities jumped 1402000.0% — and 2025, when it slumped 392.38%.
- Lineage Cell Therapeutics' Cash from Financing Activities stood at $122000.0 in 2022, then sank by 110.66% to -$13000.0 in 2023, then surged by 167284.62% to $21.7 million in 2024, then decreased by 6.23% to $20.4 million in 2025, then tumbled by 72.71% to $5.6 million in 2026.
- The last three Cash from Financing Activities figures came in at $5.6 million (Q1 2026), $20.4 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | 5.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.56 Mn |
| Mar 31, 2026 | 5.56 Mn |
| Dec 31, 2025 | 20.38 Mn |
| Dec 31, 2025 | 20.38 Mn |
| Sep 30, 2025 | 1.83 Mn |
| Sep 30, 2025 | 1.83 Mn |
| Jun 30, 2025 | -307,000.00 |
| Jun 30, 2025 | -307,000.00 |
| Mar 31, 2025 | 5.04 Mn |
| Mar 31, 2025 | 5.04 Mn |
| Dec 31, 2024 | 21.73 Mn |
| Dec 31, 2024 | 21.73 Mn |
| Sep 30, 2024 | -3,000.00 |
| Sep 30, 2024 | -3,000.00 |
| Jun 30, 2024 | 105,000.00 |
| Jun 30, 2024 | 105,000.00 |
| Mar 31, 2024 | 14.02 Mn |
| Mar 31, 2024 | 14.02 Mn |
| Dec 31, 2023 | -13,000.00 |
| Dec 31, 2023 | -13,000.00 |